Drug intelligence / Profile preview

PRX019

Development stage: Phase 1
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

PRX019 is an investigational monoclonal antibody developed for the treatment of neurodegenerative diseases. The drug is being advanced through a collaboration between Prothena and Bristol Myers Squibb. While the precise molecular target and mechanism of action remain undisclosed, it is positioned as a potential disease-modifying therapy for conditions characterized by protein dysregulation in the nervous system. The U.S. FDA cleared its IND application in December 2023, and Phase 1 clinical trials are expected to begin by late 2024 or early 2025[1][3][6]. Preclinical development has included indications such as Alzheimer's disease and amyotrophic lateral sclerosis[3]. As of mid-2025, no specific mechanism or protein target has been publicly disclosed.

Other names: PRX 019PRX019PRX-019

Beyond the preview

Go deeper on PRX019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRX019.

Explore the full profile